CY1122828T1 - Συνδυαστικη μορφη δοσολογιας ενος ανταγωνιστη υποδοχεα οπιοειδους mu και ενος παραγοντα οπιοειδους - Google Patents
Συνδυαστικη μορφη δοσολογιας ενος ανταγωνιστη υποδοχεα οπιοειδους mu και ενος παραγοντα οπιοειδουςInfo
- Publication number
- CY1122828T1 CY1122828T1 CY20201100246T CY201100246T CY1122828T1 CY 1122828 T1 CY1122828 T1 CY 1122828T1 CY 20201100246 T CY20201100246 T CY 20201100246T CY 201100246 T CY201100246 T CY 201100246T CY 1122828 T1 CY1122828 T1 CY 1122828T1
- Authority
- CY
- Cyprus
- Prior art keywords
- opioid
- dosage form
- combination dosage
- receptor antagonist
- release
- Prior art date
Links
- 239000002552 dosage form Substances 0.000 title abstract 3
- 239000002623 mu opiate receptor antagonist Substances 0.000 title abstract 3
- 239000003795 chemical substances by application Substances 0.000 title 1
- 229950007844 axelopran Drugs 0.000 abstract 1
- ATLYLVPZNWDJBW-KIHHCIJBSA-N chembl3137313 Chemical compound NC(=O)C1=CC=CC([C@H]2C[C@H]3CC[C@H](N3CCN(CC3CCCCC3)C(=O)[C@@H](O)CO)C2)=C1 ATLYLVPZNWDJBW-KIHHCIJBSA-N 0.000 abstract 1
- QNFFAKFVKCGLPK-WTKDUOFSSA-N chembl3137319 Chemical compound OS(O)(=O)=O.NC(=O)C1=CC=CC([C@H]2C[C@H]3CC[C@H](N3CCN(CC3CCCCC3)C(=O)[C@@H](O)CO)C2)=C1 QNFFAKFVKCGLPK-WTKDUOFSSA-N 0.000 abstract 1
- 238000013270 controlled release Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000003612 morphinomimetic agent Substances 0.000 abstract 1
- 230000002093 peripheral effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 230000002459 sustained effect Effects 0.000 abstract 1
- 238000013268 sustained release Methods 0.000 abstract 1
- 239000012730 sustained-release form Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562141981P | 2015-04-02 | 2015-04-02 | |
| PCT/US2016/025176 WO2016161069A1 (en) | 2015-04-02 | 2016-03-31 | Combination dosage form of a mu opioid receptor antagonist and an opioid agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122828T1 true CY1122828T1 (el) | 2021-05-05 |
Family
ID=55806767
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20201100246T CY1122828T1 (el) | 2015-04-02 | 2020-03-17 | Συνδυαστικη μορφη δοσολογιας ενος ανταγωνιστη υποδοχεα οπιοειδους mu και ενος παραγοντα οπιοειδους |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US20160287573A1 (enExample) |
| EP (1) | EP3277278B1 (enExample) |
| JP (2) | JP6713483B2 (enExample) |
| KR (1) | KR20170132325A (enExample) |
| CN (1) | CN107820424B (enExample) |
| AU (1) | AU2016243691A1 (enExample) |
| BR (1) | BR112017021120A2 (enExample) |
| CA (1) | CA2980328A1 (enExample) |
| CY (1) | CY1122828T1 (enExample) |
| DK (1) | DK3277278T3 (enExample) |
| ES (1) | ES2774473T3 (enExample) |
| HK (1) | HK1247105A1 (enExample) |
| HR (1) | HRP20200432T1 (enExample) |
| HU (1) | HUE048785T2 (enExample) |
| IL (1) | IL254593A0 (enExample) |
| LT (1) | LT3277278T (enExample) |
| ME (1) | ME03671B (enExample) |
| MX (1) | MX2017012474A (enExample) |
| PH (1) | PH12017501767A1 (enExample) |
| PL (1) | PL3277278T3 (enExample) |
| PT (1) | PT3277278T (enExample) |
| RS (1) | RS60074B1 (enExample) |
| RU (1) | RU2017134794A (enExample) |
| SI (1) | SI3277278T1 (enExample) |
| SM (1) | SMT202000157T1 (enExample) |
| TW (1) | TW201642856A (enExample) |
| WO (1) | WO2016161069A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3277278B1 (en) | 2015-04-02 | 2020-01-08 | Theravance Biopharma R&D IP, LLC | Combination dosage form of a mu opioid receptor antagonist and an opioid agent |
| WO2019031560A1 (ja) * | 2017-08-08 | 2019-02-14 | 日本合成化学工業株式会社 | 医薬錠剤、およびその製造方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2412409T3 (es) | 1997-12-22 | 2013-07-11 | Euro-Celtique S.A. | Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo |
| US6419960B1 (en) | 1998-12-17 | 2002-07-16 | Euro-Celtique S.A. | Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations |
| US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
| AR029538A1 (es) * | 2000-07-06 | 2003-07-02 | Wyeth Corp | Composiciones farmaceuticas de agentes estrogenicos |
| US7842307B2 (en) | 2001-08-06 | 2010-11-30 | Purdue Pharma L.P. | Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent |
| DK1414451T3 (da) * | 2001-08-06 | 2009-08-10 | Euro Celtique Sa | Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist |
| AU2003301121A1 (en) * | 2002-12-18 | 2004-07-14 | Pain Therapeutics, Inc. | Oral dosage forms with therapeutically active agents in controlled release cores and immediate release gelatin capsule coats |
| US20050013863A1 (en) | 2003-07-18 | 2005-01-20 | Depomed, Inc., A Corporation Of The State Of California | Dual drug dosage forms with improved separation of drugs |
| AU2004314693B2 (en) | 2003-09-26 | 2011-04-07 | Alza Corporation | Drug coating providing high drug loading and methods for providing the same |
| TWI415635B (zh) | 2004-05-28 | 2013-11-21 | 必治妥施貴寶公司 | 加衣錠片調製物及製備彼之方法 |
| AU2006218603A1 (en) * | 2005-03-02 | 2006-09-08 | Theravance, Inc. | Quinolinone compounds as 5-HT4 receptor agonists |
| MY145633A (en) | 2006-03-01 | 2012-03-15 | Theravance Inc | 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists |
| CN101395154B (zh) * | 2006-03-01 | 2011-01-19 | 施万制药 | 作为μ阿片受体拮抗剂的8-氮杂双环[3.2.1]辛烷化合物 |
| CN101500542A (zh) * | 2006-07-11 | 2009-08-05 | 共有药物有限公司 | 控释制剂 |
| TWI409067B (zh) | 2007-02-28 | 2013-09-21 | Theravance Inc | ８-氮雜雙環〔３．２．１〕辛烷化合物之結晶型 |
| TWI415850B (zh) | 2007-07-20 | 2013-11-21 | Theravance Inc | 製備ｍｕ類鴉片受體拮抗劑之中間物的方法 |
| AU2009244190B2 (en) * | 2008-05-07 | 2016-02-25 | Salix Pharmaceuticals, Ltd. | Methods of treating bowel disease by administering a bowel cleanser and an antibiotic |
| EP2210595A1 (en) | 2009-01-14 | 2010-07-28 | LEK Pharmaceuticals d.d. | Active coating of pharmaceutical dosage forms |
| MX2011011919A (es) * | 2009-05-12 | 2012-01-27 | Bpsi Holdings Llc | Sistemas de recubrimiento de pelicula de liberacion inmediata con barrera contra humedad mejorada y sustratos recubiertos con dichos sistemas. |
| IT1398930B1 (it) * | 2010-03-24 | 2013-03-28 | Molteni & C | Formulazioni farmaceutiche bistrato contenenti agonisti ed antagonisti oppioidi. |
| AU2011295837B2 (en) * | 2010-09-03 | 2015-06-18 | Astrazeneca Uk Limited | Drug formulations using water soluble antioxidants |
| ES2801725T3 (es) | 2011-02-01 | 2021-01-12 | Bristol Myers Squibb Co | Formulaciones farmacéuticas que incluyen un compuesto de amina |
| US9339489B2 (en) * | 2013-03-15 | 2016-05-17 | Aprecia Pharmaceuticals Company | Rapid disperse dosage form containing levetiracetam |
| EP3277278B1 (en) | 2015-04-02 | 2020-01-08 | Theravance Biopharma R&D IP, LLC | Combination dosage form of a mu opioid receptor antagonist and an opioid agent |
-
2016
- 2016-03-31 EP EP16718062.9A patent/EP3277278B1/en active Active
- 2016-03-31 RU RU2017134794A patent/RU2017134794A/ru not_active Application Discontinuation
- 2016-03-31 BR BR112017021120-3A patent/BR112017021120A2/pt not_active Application Discontinuation
- 2016-03-31 HR HRP20200432TT patent/HRP20200432T1/hr unknown
- 2016-03-31 TW TW105110406A patent/TW201642856A/zh unknown
- 2016-03-31 US US15/086,816 patent/US20160287573A1/en not_active Abandoned
- 2016-03-31 RS RS20200315A patent/RS60074B1/sr unknown
- 2016-03-31 CA CA2980328A patent/CA2980328A1/en not_active Abandoned
- 2016-03-31 KR KR1020177031800A patent/KR20170132325A/ko not_active Withdrawn
- 2016-03-31 DK DK16718062.9T patent/DK3277278T3/da active
- 2016-03-31 ME MEP-2020-48A patent/ME03671B/me unknown
- 2016-03-31 PL PL16718062T patent/PL3277278T3/pl unknown
- 2016-03-31 WO PCT/US2016/025176 patent/WO2016161069A1/en not_active Ceased
- 2016-03-31 SI SI201630671T patent/SI3277278T1/sl unknown
- 2016-03-31 SM SM20200157T patent/SMT202000157T1/it unknown
- 2016-03-31 LT LTEP16718062.9T patent/LT3277278T/lt unknown
- 2016-03-31 HK HK18106740.0A patent/HK1247105A1/zh unknown
- 2016-03-31 CN CN201680019821.7A patent/CN107820424B/zh active Active
- 2016-03-31 HU HUE16718062A patent/HUE048785T2/hu unknown
- 2016-03-31 MX MX2017012474A patent/MX2017012474A/es unknown
- 2016-03-31 JP JP2017550832A patent/JP6713483B2/ja active Active
- 2016-03-31 AU AU2016243691A patent/AU2016243691A1/en not_active Abandoned
- 2016-03-31 ES ES16718062T patent/ES2774473T3/es active Active
- 2016-03-31 PT PT167180629T patent/PT3277278T/pt unknown
-
2017
- 2017-09-19 IL IL254593A patent/IL254593A0/en unknown
- 2017-09-26 PH PH12017501767A patent/PH12017501767A1/en unknown
- 2017-10-31 US US15/798,647 patent/US10369142B2/en active Active
-
2019
- 2019-06-27 US US16/454,353 patent/US10946009B2/en active Active
-
2020
- 2020-02-04 JP JP2020016858A patent/JP2020073583A/ja not_active Withdrawn
- 2020-03-17 CY CY20201100246T patent/CY1122828T1/el unknown
-
2021
- 2021-02-08 US US17/248,787 patent/US11452723B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124293T1 (el) | Αγωνιστης υποδοχεα γλυκοκορτικοειδων και ανοσοσυζευγματα αυτου | |
| BR112017010198A2 (pt) | terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1 | |
| DK3555064T3 (da) | GLP-1 receptoragonister og anvendelser deraf | |
| EP3609888A4 (en) | FARNESOID X RECEPTOR AGONISTS AND THEIR USES | |
| CY1123592T1 (el) | Αναστολεας κινασης aurora a | |
| EP3596053A4 (en) | FARNESOID X RECEPTOR AGONISTS AND THEIR USES | |
| DK3500593T3 (da) | Ukendte t-cellereceptorer og immunterapi under anvendelse deraf | |
| CL2017000590A1 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| DK3551221T3 (da) | Hidtil ukendte t-cellereceptorer og immunterapi med anvendelse deraf | |
| BR112016013963A2 (pt) | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| MX2016015263A (es) | Anticuerpos humanos frente a la proteina de anclaje del coronavirus causante del sindrome respiratorio de oriente medio. | |
| MX2016002137A (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| BR112016026378A2 (pt) | formulações e métodos para tratamento com queratina | |
| BR112016017256A2 (pt) | combinação de um antagonista de pd-1 e um inibidor de vegfr para o tratamento de câncer | |
| DK3169703T3 (da) | Kimær antigenreceptor og anvendelse deraf | |
| MA46430A (fr) | Thérapie combinée d'agonistes de cnp à libération contrôlée | |
| MA50175A (fr) | Formulation de valbenazine à dosage élevé et compositions, procédés et kits associés | |
| EP3852737A4 (en) | Farnesoid x receptor agonists and uses thereof | |
| EP3630763A4 (en) | CORTICOTROPIN RELEASE FACTOR RECEPTOR ANTAGONISTS | |
| EP3628005A4 (en) | Corticotropin releasing factor receptor antagonists | |
| EP3525779C0 (de) | Kombination enthaltend den sgc stimulator vericuguat und den mineralcorticoid-rezeptor-antagonist finerenone | |
| DK3903772T3 (da) | Sammensætninger indeholdende en opioid vækstfaktorreceptor (ogfr)-antagonist til brug i fremme af knogledannelse og i behandling af kræft | |
| BR112017012366A2 (pt) | desalojamento e liberação de hsc usando antagonista de alfa-9-integrina e antagonista de cxcr4. | |
| IL283511A (en) | Dendrimer for therapy and imaging |